Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
CytomX Therapeutics, Inc. CTMX
$1.82
+$0.05 (2.54%)
На 18:00, 12 мая 2023
+75.82%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
116093075.00000000
-
week52high
3.02
-
week52low
1.17
-
Revenue
53163000
-
P/E TTM
-1
-
Beta
0.64878800
-
EPS
-1.45000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Neutral | Buy | 11 июл 2022 г. |
| Cowen & Co. | Market Perform | Outperform | 11 июл 2022 г. |
| Wedbush | Neutral | Outperform | 07 июл 2022 г. |
| Jefferies | Hold | Buy | 07 июл 2022 г. |
| BTIG | Buy | Buy | 07 июл 2022 г. |
| BMO Capital | Market Perform | Outperform | 14 ноя 2022 г. |
| JP Morgan | Underweight | Overweight | 10 ноя 2022 г. |
| BMO Capital | Market Perform | Market Perform | 06 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| ROWLAND LLOYD A | A | 22500 | 22500 | 10 авг 2022 г. |
| ROWLAND LLOYD A | A | 135000 | 135000 | 10 авг 2022 г. |
| Ogden Christopher | A | 13750 | 13750 | 10 авг 2022 г. |
| Ogden Christopher | A | 82500 | 82500 | 10 авг 2022 г. |
| Landau Jeffrey B | A | 22500 | 22500 | 10 авг 2022 г. |
| Landau Jeffrey B | A | 135000 | 135000 | 10 авг 2022 г. |
| McCarthy Sean A. | A | 75000 | 75000 | 10 авг 2022 г. |
| McCarthy Sean A. | A | 450000 | 450000 | 10 авг 2022 г. |
| Peterson Amy C. | D | 62690 | 7463 | 20 июл 2022 г. |
| Landau Jeffrey B | D | 30725 | 4206 | 20 июл 2022 г. |
Новостная лента
CytomX Therapeutics, Inc. (CTMX) Q1 2023 Earnings Call Transcript
Seeking Alpha
09 мая 2023 г. в 23:13
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q1 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Chris Ogden - SVP, Finance & Accounting Sean McCarthy - CEO, Chairman Conference Call Participants Mitchell Kapoor - H.C. Wainwright Malcolm Kuno - JP Morgan Roger Song - Jefferies Operator Good afternoon, everyone.
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 19:07
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.37 per share a year ago.
CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023
GlobeNewsWire
01 мая 2023 г. в 16:01
SOUTH SAN FRANCISCO, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report first quarter financial results on Tuesday, May 9, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
GlobeNewsWire
25 апр 2023 г. в 16:05
SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ on Tuesday, May 2, 2023 at 11:00 a.m. ET.
CytomX Therapeutics, Inc. (CTMX) Q4 2022 Earnings Call Transcript
Seeking Alpha
27 мар 2023 г. в 19:51
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2022 Earnings Conference Call March 27, 2023 5:00 PM ET Company Participants Chris Ogden - SVP of Finance and Accounting Sean McCarthy - CEO and Chairman Conference Call Participants Roger Song - Jefferies Mara Goldstein - Mizuho Group Peter Lawson - Barclays Mitchell Kapoor - H.C. Wainwright Anupam Rama - JPMorgan Etzer Darout - BMO Capital Markets Operator Good day and thank you for standing by.